BT-1718 is under clinical development by Bicycle Therapeutics and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Cancer have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BT-1718’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BT-1718 overview
BT-1718 is under development for the treatment of solid tumors including squamous non-small cell lung cancer, gastric, non-small cell lung cancer, bladder, esophageal squamous cell carcinoma. It is administered through the intravenous route. The drug comprises of bicyclic peptide conjugated to the maytansinoid toxin. It is developed based on bicyclic peptide technology composed of peptides in combination with a matrix of different linkers for the delivery of a cytotoxic payload. The peptide acts by targeting cells expressing membrane type 1 matrix metalloproteinase (MMP14). It is developed based on bicycle toxin conjugate technology.
It was also under development for sarcoma and triple negative breast cancer.
Bicycle Therapeutics overview
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of molecules for the treatment of cancers and other debilitating diseases. The company’s Bicycle Toxin Conjugates (BTC) pipeline includes BT1718, BT5528, and BT8009 for the indication of metastatic urothelial cancer and others. Its Immuno-oncology pipeline products include BT7480, BT7401 and BT7455. Bicycle Therapeutics collaborates with other biotechnology companies for the development of bicyclic peptide inhibitors for the treatment of ophthalmic diseases such as diabetic macular edema, renal elimination, versatility for multimerization and conjugation. The company operates in the UK and the US. Bicycle Therapeutics is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of BT-1718’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
